Abstract
The latest research data shows that the cause of death of liver cancer patients ranks third among malignant tumors. The global situation of early detection, early diagnosis and early treatment of liver cancer is severe. Therefore, how to achieve early diagnosis of liver cancer has important clinical significance. At present, alpha-fetoprotein, alpha-fetoprotein-L3 and des-gamma-carboxythrombin are commonly used in the clinical detection of hepatocellular carcinoma; however, their sensitivity cannot meet the diagnostic needs of patients with early liver cancer. With the development of molecular biology techniques such as serum oligosaccharide chains detection, B10, a member of the aldehyde ketone reductase family, microRNAs, circulating tumor cells, DNA methylation, and other novel serum biomarkers, a new option for the early screening and diagnosis of hepatocellular carcinoma patients will be offered.